anti-CD38 A2 CAR-T cells / Celularity, Sorrento - LARVOL DELTA

SOR-CART-MM-001 Study: A Phase I, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) (ASH 2023) - P1b | "A single dose of CAR2 Anti-CD38 CAR-T cells was administered 2 days post lymphodepletion with single-agent cyclophosphamide 1. This phase I trial demonstrated that CAR2 anti-CD38 A2 CAR-T cells were generally well tolerated at the Cohort 2 (MTD) dose and demonstrated objective though short responses even in patients progressing after daratumumab and belantamab mafodotin. More clinical studies are needed to optimize the efficacy and tolerability of CAR-T cell therapies for patients with RRMM. This study was completed, and no more patients will be enrolled."

CAR T-Cell Therapy • Clinical • PK/PD data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Novel Coronavirus Disease • Oncology • Septic Shock

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients (clinicaltrials.gov) - P1 | N=10 | Completed | Sponsor: Sorrento Therapeutics, Inc. | Active, not recruiting ➔ Completed | N=72 ➔ 10

CAR T-Cell Therapy • Enrollment change • Trial completion • Hematological Malignancies • Multiple Myeloma • Oncology

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients (clinicaltrials.gov) - P1; N=72; Active, not recruiting; Sponsor: Sorrento Therapeutics, Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Hematological Malignancies • Multiple Myeloma • Oncology

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients (clinicaltrials.gov) - P1; N=72; Recruiting; Sponsor: Sorrento Therapeutics, Inc.; Trial completion date: Feb 2021 ➔ Feb 2022; Trial primary completion date: Sep 2020 ➔ Sep 2021

Clinical • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients (clinicaltrials.gov) - P1; N=72; Recruiting; Sponsor: Sorrento Therapeutics, Inc.; Trial completion date: Sep 2020 ➔ Feb 2021; Trial primary completion date: Apr 2020 ➔ Sep 2020

Clinical • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology